Coherus Oncology (CHRS) Receivables - Other (2013 - 2026)

Coherus Oncology has disclosed Receivables - Other across 6 years of filings, most recently posting $446000.0 for Q1 2026.

• Receivables - Other for Q1 2026 came in at $446000.0, down 77.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $446000.0 (down 77.1% YoY), and the FY2025 annual result was $603000.0, down 94.52% from the prior year.
• Receivables - Other came in at $446000.0 for Q1 2026 at Coherus Oncology, down from $603000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $241.3 million in Q3 2025 to a low of $446000.0 in Q1 2026.
• The 3-year median for Receivables - Other is $31.2 million (2024), against an average of $63.5 million.
• Peak annual rise in Receivables - Other reached 672.23% in 2025, while the deepest fall reached 94.52% in 2025.
• Coherus Oncology's Receivables - Other stood at $11.0 million in 2024, then tumbled by 94.52% to $603000.0 in 2025, then slipped by 26.04% to $446000.0 in 2026.
• The last three Receivables - Other figures came in at $446000.0 (Q1 2026), $603000.0 (Q4 2025), and $241.3 million (Q3 2025), per Business Quant data.